Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry
Objective Biologic therapies have revolutionized the management of moderate-to-severe psoriasis; however, there are a limited number of US real-world studies characterizing patients based on response to these treatments. This study examined characteristics at enrollment and change in outcomes of US...
Main Authors: | Abby S. Van Voorhees, Marc A. Mason, Leslie R. Harrold, Ning Guo, Adriana Guana, Haijun Tian, Vivian Herrera, Bruce E. Strober |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-11-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09546634.2020.1720586 |
Similar Items
-
Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry
by: Abby S. Van Voorhees, et al.
Published: (2021-04-01) -
US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry
by: Bruce E. Strober, et al.
Published: (2020-05-01) -
Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience
by: Melis Gönülal, et al.
Published: (2023-12-01) -
Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
by: Norman Wasel, et al.
Published: (2020-05-01) -
Ustekinumab en psoriasis cutánea y artritis psoriásica
by: Javier E. Rosa, et al.
Published: (2015-06-01)